determining the effect of magnesium,vitamin b6 and b6-magnesium combination on premenstrual syndrome in the affected persons that going to medical health centers of isfahan university

INTERVENTION: Intervention 1: Magnesium That consist of magnesium oxide (MgO) powder that produced by MERK company and Drug faculty of Isfahan University will make these productions in the shapes of 250 milligram magnesium tablet.the patients will use one tablet daily. Intervention 2: vitamin B6: Magnesium That consist of pyridoxine powder that produced by MERK company and Drug faculty of Isfahan University will make these productions in the shapes of 40 milligram vitamin B6 tablet.the patients will use one tablet daily. Intervention 3: placebo That consist of starch and Drug faculty of Isfahan University will make these productions in the shape of tablet.the patients will use one tablet daily. Intervention 4: magnesium+vitamin b6 That consist of pyridoxine +magnesium oxide(MgO)powder that produced by MERK company and Drug faculty of Isfahan University will make these productions in the shapes of 40 milligram vitamin B6+250 milligram magnesium tablet.the patients will use one tablet daily. Magnesium That consist of magnesium oxide (MgO) powder that produced by MERK company and Drug faculty of Isfahan University will make these productions in the shapes of 250 milligram magnesium tablet.the patients will use one tablet daily. magnesium+vitamin b6 That consist of pyridoxine +magnesium oxide(MgO)powder that produced by MERK company and Drug faculty of Isfahan University will make these productions in the shapes of 40 milligram vitamin B6+250 milligram magnesium tablet.the patients will use one tablet daily. placebo That consist of starch and Drug faculty of Isfahan University will make these productions in the shape of tablet.the patients will use one tablet daily. Placebo Treatment ‐ Drugs vitamin B6: Magnesium That consist of pyridoxine powder that produced by MERK company and Drug faculty of Isfahan University will make these productions in the shapes of 40 milligram vitamin B6 tablet.the patients will use one tablet daily. CONDITION: premenstrual syndrome. ; Premenstrual tension syndrome Premenstrual tension syndrome PRIMARY OUTCOME: Premenstrual syndrome severity. Timepoint: 2 month before and 2 month after intervention. Method of measurement: questionnaire. SECONDARY OUTCOME: . Timepoint: . Method of measurement: . INCLUSION CRITERIA: Inclusion criterial: The study population will be women of 45‐15 referred to the selected health centers; who were affected by the PMS according to the criteria of American Psychiatry Association; and also met the inclusion criteria; being 45‐15 years old; having regular menstrual cycle; not being affected by depression or anxiety; not having an acute or chronic disease; not taking medicines or supplements; and not taking regular exercise) exclusion criterial: will be pregnancy; willingness to use hormonal contraceptive methods or taking hormonal treatment; not taking the drug or not filling out the forms regularly; and unwillingness to continue the treatment